Collaborative Research Database

The CBTDDC is committed to strengthening collaborations between an international, multi-disciplinary network of clinicians and researchers whose combined expertise will accelerate the development of drug delivery systems that target brain diseases.

With this in mind, we are developing this Collaborative Research Database. We believe that this database will offer unrivalled opportunities for open dialogue, sharing of resources and collaborative research. But its success will depend on the number of researchers who submit their details for inclusion. We strongly encourage you to help make this a powerful research tool by submitting your details for inclusion. Thank you.

 

Alexander-Cameron

Cameron Alexander

Professor of Polymer Therapeutics University of Nottingham, UK School of Pharmacy I lead the Division of Molecular Therapeutics and Formulation at the School of Pharmacy in Nottingham. The main areas of research within Polymer Therapeutics are the synthesis and characterisation of bioresponsive materials and externally-activated biosensing and release polymers. These polymers can be triggered to release signals or therapeutic cargoes by heat, light, pH, redox and enzymatic activity. Bioresponsive polymers drug delivery biomaterials synthesis

Battaglia-Giuseppe

Giuseppe Battaglia

Chair of Molecular Bionics University College London, UK Nanomedicine, Cancer targeting, and BBB biophysics I am the Chair of Molecular Bionics and Honorary Professor of Chemical Engineering in the Department of Chemistry at the University College London. Several of our activities involve the design of novel carriers to target cancer cells and/or cross the blood-brain barrier. We have developed a workflow of activities that allows the design of super-selective nanocarriers, their study in complex in vitro models and finally the pre-clinical validation in relevant models. Nanomedicine polymersomes blood brain barrier (BBB) cancer targeting

Boyd-Marie

Marie Boyd

Reader in Translation Cancer Research Radiobiology University of Strathclyde, UK Twenty years experience in combination therapeutics including translation of clinical schemes in paediatric populations. Extensive experience as PI and CI of multidisciplinary scientific and training grants in the cancer field. Experience with brain tumour 2D and 3D models and interrogation of chemo- and radio-therapeutics in vivo. Extensive clinical and industrial network in the brain tumour arena. 2D models 3D models chemotherapeutics radiotherapeutics

Brem-Henry

Henry Brem

Professor of Neurosurgery, Ophthalmology, Oncology and Biomedical Engineering Johns Hopkins University, USA I have led a neurosurgical brain tumor research team since 1984, and have extensive PI/CI experience on brain tumor and neuro-oncology grants. My team invented and developed Gliadel® wafers to intraoperatively deliver chemotherapy to brain tumors. This work has been expanded to include local delivery of anti-angiogenic therapies, chemotherapeutic agents and resistance modifiers for primary and metastatic brain tumors. I have worked with collaborators to develop and synthesize new classes of polymers and microchips for drug delivery. Tumor type: rodent brain tumor cell lines, established human glioma lines, primary cell lines derived from patient samples. immunotherapy Gliadel intraoperative chemotherapy microchips polymers rodent brain tumour cell lines established human glioma lines primary cell lines localised drug delivery

Cima-Michael

Michael Cima

Professor of Engineering Massachusetts Institute of Technology, USA Koch Institute of Integrative Cancer Research Lead a research lab focusing on developing medical devices for single compartment drug delivery with a history of clinical translation. Currently developing a minimally invasive device for chronic fluid infusion and electrical interfacing with discrete deep-brain structures. Experience as a founder of four startup companies and consulting for several pharmaceutical companies. Medical Devices micropump localized drug delivery neural implant

Cohen-Kenneth

Kenneth Cohen

Professor (Oncology and Pediatrics) Johns Hopkins University, USA Experienced clinical trialist with a particular focus on small scale clinical trial design. Previous and ongoing research related to local drug delivery including the original development of Gliadel® in children and intra-arterial chemotherapy for children with DIPG. Tumor type: All pediatric brain tumors. clinical trial design Gliadel intra-arterial

De-Vleeschouwer-Steven

Steven De Vleeschouwer

Staff neurosurgeon / Professor University Hospitals Leuven, KU Leuven, Belgium Experimental neurosurgery and neuroanatomy Preclinical and conceptual research in nose-to-brain delivery of innovative therapeutics including formulated RNAi substances. Preclinical research in consortium for development of multichannel microcatheter for CED in brain tumors including brainstem locations. nose-to-brain transport tumor micro-environment RNAi CED convection-enhanced delivery intra-nasal intranasal

Green-Adam

Adam Green

Assistant Professor of Pediatrics Children's Hospital, Colorado, USA Pediatric high-grade glioma One of my areas of investigation is systemic chemotherapy penetration to pediatric glioblastoma and DIPG in patient-derived xenograft models and clinical trials. chemotherapy penetration glioblastomas DIPG model

Green-Jordan-J

Jordan J Green

Associate Professor of Biomedical Engineering, Neurosurgery, Oncology, Ophthalmology, Materials Science & Engineering, and Chemical & Biomolecular Engineering Johns Hopkins University, USA My previous and ongoing research focuses on drug, gene and cellular therapies to treat brain tumors. At Johns Hopkins University School of Medicine, I direct the Biomaterials and Drug Delivery Laboratory, serve on the executive committee of the Institute for NanoBioTechnology, and am associate director of the Translational Tissue Engineering Center. I am also Vice Chair of the Drug Delivery Special Interest Group of the Society For Biomaterials. My areas of expertise are: drug delivery systems, biomaterials, nanotechnology, non-viral gene therapy, immunotherapy and cell therapy. Tumor type: All pediatric brain tumors. biomaterials nanotechnology non-viral gene therapy cell therapy immunotherapy stem cells

Grundy-Richard

Richard Grundy

Professor of Neuro-Oncology and Cancer Biology / Co-Director CBTRC University of Nottingham, UK Children's Brain Tumour Research Centre (CBTRC) My expertise lies in molecular neuro-oncology, functional imaging, biomarkers, localised drug delivery systems and clinical trials. In particular, I have significant expertise in intraventricular chemotherapy predominantly using etoposide. I am also chief UK investigator for the SIOP ependymoma II trial. Tumour type: Ependymoma, High Grade Glioma, Medulloblastoma. functional imaging biomarkers clinical trials polymers high grade glioma HGG medulloblastoma localised delivery Ependymoma

Hales-Patrick

Patrick Hales

Children with Cancer UK Research Fellow University College London, UK My research area covers advanced MRI techniques for improved diagnosis and monitoring of treatment response in paediatric cancer. I specialize in the development of new imaging techniques for measuring the cellular and vascular structure of paediatric brain tumours. I am currently leading the integration of these techniques into clinical practice at Great Ormond Street Children's Hospital. Using these techniques, we can monitor the blood supply to a tumour, which will have a strong influence on the efficacy of drug delivery. Changes in the tumour microstructure as a response to treatment can also be measured. Magnetic Resonance Imaging diffusion-weighted imaging perfusion-weighted imaging paediatric cancer MRI

Hargrave-Darren

Darren Hargrave

Reader in Paediatric Neuro-Oncology and Consultant Paediatric Neuro-Oncologist University College London, Institute of Child Health / Great Ormond Street Hospital, UK I have expertise in drug development and am an experienced chief investigator in early and late phase clinic trials. I have strong links with pharmaceutical partners and am Chair of the UK Novel Agents subgroup. My collaborations with UCL/GOSH colleagues in drug delivery include: novel nanotechnology- polymersomes, intra-arterial chemotherapy delivery (retinoblastoma) and interest in CED. Tumour type: all paediatric brain tumours. clinical trials nanotechnology polymers intra-arterial delivery convection-enhanced delivery CED

Janowski-Miroslaw

Miroslaw Janowski

Associate Professor Johns Hopkins University, USA Expertise in intra-arterial drug delivery using MRI guidance. intra-arterial MRI

Jones-Arwyn

Arwyn Jones

Professor of Membrane Traffic and Drug Delivery Cardiff University, Wales, UK School of Pharmacy and Pharmaceutical Sciences I have been developing in vitro assays for analysing transcytosis in murine bEnd3 cells and human brain derived microvascular endothelial cells. This is for monitoring delivery and intracellular traffic of ligands, nanoparticles and antibodies. This was achieved using techniques such as live cell imaging, confocal microscopy and flow cytometry. drug delivery nanoparticles endocytosis cancer cell biology public engagement in science

Katsila-Theodora

Theodora Katsila

Senior Research Scientist University of Patras, Greece My research focus spans pan-omics strategies coupled to information technologies toward better-informed decision-making and genotype-to-phenotype correlations. Sharing both academic and industrial research experience, I have interdisciplinary wet- and dry-lab expertise. 3D omics biomarkers

Kortylewski-Marcin

Marcin Kortylewski

Associate Professor Beckman Research Institute at City of Hope, USA Cancer immunotherapy My group focuses on the development of oligonucleotide-based cancer immunotherapies. We demonstrated the feasibility of using TLR9 agonists, CpG DNA, for targeted delivery of therapeutic STAT3 siRNA or ASO to immune cells infiltrating solid tumors, such as glioma. The first two generations of CpG-STAT3 inhibitors are undergoing safety/tolerability studies assisting IND filing for therapy of human B cell lymphoma and malignant glioma. I am an active member of the Oligonucleotide Therapeutics Society (Advisory Council Member), ASGCT and AACR. oligonucleotide therapeutics Cancer immunotherapy siRNA CpG STAT3 TLR9

McGuire-Kerry

Kerry McGuire

Undergraduate Student University of Strathclyde, UK Pharmacy Currently undertaking a dissertation on the use of PD-1 inhibitors in paediatric brain tumours.

Mullen-Alexander

Alexander Mullen

Professor of Pharmacy Practice University of Strathclyde, UK I am a qualified pharmacist with clinical, industrial and academic experience in drug and delivery device development with an ongoing interest in the treatment of cancers, including those of the central nervous system. My expertise lies in designing injectable/implantable devices that can deliver a variety of drugs and nanoparticles over prolonged periods with a view to minimising the recurrence of cancer from the tumour margins left after standard neurosurgery interventions. These treatments are to synergise with other treatment modalities such as radiotherapy. Tumour type: glioma- and medulloblastoma-derived cell lines. nanoparticles glioma cell lines medulloblastoma cell lines device development polymers formulation Analysis

Needham-David

David Needham

Honorary Professor University of Nottingham, UK Nanomedicines New endogenous-inspired nanoparticle designs for metastatic cancer, including: synthesis, characterisation, and formulation of the pro-drug Niclosamide Stearate (NSNP); NSNP testing in vitro for cell-uptake and cytotoxicity in glioblastoma, breast and prostate cancers; and in vivo preclinical studies showing encouraging results in flank and metastatic tumours with growth delays and extended lifetimes for the NSNP-treated animals. Also includes PET-imageable nanoparticles which, in combination with the NSNPs, forms a suite of diagnostic and therapeutic "Individualised nano-medicines" for cancer. Nanomedicines cancer prodrugs

Pearl-Monica

Monica S. Pearl

Associate Professor of Radiology Johns Hopkins University, USA Division of Interventional Neuroradiology, School of Medicine I have extensive clinical and research expertise with catheter-based intra-arterial therapies for adult and pediatric neurovascular disorders of the brain and spine. My neuroradiology background allows for developing complementary neuroimaging platforms to manipulate the blood brain barrier and better define drug distribution. I am PI for two active clinical trials for IA drug delivery (NCT01293539 and NCT01688401) for retinoblastoma and DIPG. Tumor type: DIPG, Retinoblastoma. DIPG retinoblastoma intra-arterial Imaging

Rahman-Ruman

Ruman Rahman

Assistant Professor of Molecular Neuro-Oncology University of Nottingham, UK My research group has developed a localised drug delivery system in which a biodegradable polymer (PLGA/PEG) is applied around the tumour cavity wall at neurosurgical resection. The polymer forms a paste at room temperature, which solidifies next to the surgical cavity wall at body temperature. This gives spatial control over dose delivery, extending the length of time infiltrative tumour cells are exposed to the drug. My expertise covers: (1) local biomaterial-based drug delivery systems for intracranial tumours, (2) 3D brain tumour models for drug screening, (3) bio-instructive nanotherapeutics, (4) HDAC inhibitors, (5) brain intra-tumour heterogeneity. biomaterials polymers localised drug delivery intraoperative chemotherapy 3D models nanotherapeutics HDAC inhibitors intra-tumour heterogeneity.

Sánchez-Gómez-Pilar

Pilar Sánchez-Gómez

Instituto de Salud Carlos III, Spain Neurooncology We have developed models of human and mouse gliomas with different levels of BBB leakage. These models have different responses to conventional and molecular chemotherapy. Preliminary data indicates that vascular normalization could help in the penetrance of the compounds in several cases. Glioblastoma mouse models preclinical assays EGFR tumor microenvironment

Sandberg-David

David Sandberg

Principal Investigator Health Science Center and MD Anderson Cancer Center, University of Texas, USA McGovern Medical School For over a decade, I have studied local drug delivery into the fourth ventricle of the brain to treat recurrent, malignant posterior fossa tumors in children. I first studied safety and pharmacokinetics in piglets and then non-human primates. These experiments led to a promising pilot trial in humans, and we currently have several open clinical trials for children with recurrent malignant brain tumors originating in the fourth ventricle. local drug delivery Fourth ventricle

Schatzlein-Andreas

Andreas Schatzlein

Professor of Translational Therapeutics University College London, UK School of Pharmacy Drug delivery to the brain is one of our key areas of research and we have published extensively in this area. We have developed a polymer based system that increases drug transport either across the BBB or by nose-to-brain administration. For this reason we have been chosen as partner for example for the EU consortium EPITARGET - to deliver epilepsy medication. The system is being commercially developed by Nanomerics. Nanomedicine

Stanyard-Ryan

Ryan Stanyard

Student Keele University, UK Neuroscience/neuropsychology, counselling, psychotherapy, biological psychology Neuroscience student, experience studying pharmacodynamic and pharmacokinetic systems and BBB diffusion elements. Neurology placement - 1 week bespoke tailored programme made by Chair of Medicine of University Hospital of North Midlands.

van-Vuurden-Dannis

Dannis van Vuurden

Paediatric Neuro-Oncologist VU University Medical Center, Amsterdam, The Netherlands I am Chair of the SIOPE DIPG Network and Registry. My expertise lies in preclinical (combinational) drug screens, convection-enhanced delivery and MRI-guided high intensity focal ultrasound (HIFU) in DIPG, BBB-targeted liposomal drug encapsulation, clinical trials in children, and molecular drug imaging (PET imaging of radiolabeled drugs). Tumour type: paediatric high-grade glioma, diffuse midline gliomas / DIPG. preclinical drug screens combinatorial drug screens convection-enhanced delivery MRI-guided high intensity focal ultrasound HIFU DIPG liposomal delivery liposome clinical trials PET imaging high grade glioma HGG CED

Veal-Gareth

Gareth Veal

Senior Lecturer / Head of Newcastle Cancer Centre Pharmacology Group Newcastle University, UK Newcastle Cancer Centre Pharmacology Group I have expertise in clinical pharmacology, pharmacokinetics and quantification of drug levels in clinical samples (blood, plasma, CSF, tumour material, etc). My research interests lie in the development and validation of assays for the quantification of novel and established anticancer drugs and their metabolites. I am and have been CI on numerous completed and published clinical pharmacology trials. clinical pharmacology pharmacokinetics Ependymoma Assay development pharmacodynamics

Walczak-Piotr

Piotr Walczak

Associate Professor of Radiology and Radiological Science Johns Hopkins University, USA My expertise lies in molecular and cellular imaging, and regenerative medicine: (1) Monitoring of drug biodistribution using MRI. (2) Use of stem cells to reduce brain damage caused by chemotherapy. (3) Modeling human brain tumors in animals with intact immune systems. Tumor type: DIPG, Medulloblastoma, GBM. MRI drug biodistribution glial stem cells glial progenitors regenerative medicine intra-arterial DIPG medulloblastoma GBM

Walker-David

David Walker

Professor Paediatric Oncology / Co-Director CBTRC University of Nottingham, UK Children's Brain Tumour Research Centre (CBTRC) I am a Paediatric Neuro-Oncologist with expertise in clinical trials in children's cancers and in intrathecal therapy. Over the past 2 decades whilst treating children with brain tumours and contributing to the design of clinical trials, I concluded that systemically administered drugs have had relatively little impact, particularly in malignant brain tumours. Whilst treating children with leukaemia the outstanding success has been linked to successfully treating the CNS, using intra-CSF therapy and intensified systemic therapies. This experience of CNS targeting has highlighted the need to explore this further in childhood brain tumours, hence this consortium. clinical trials intrathecal delivery intra csf drug delivery Paediatric Neuro-oncology

Warren-Kathy

Katherine Warren

Senior Investigator National Cancer Institute, USA Pediatric Neuro-Oncology Section My research focuses on optimizing clinical trial design by pre-clinically evaluating pharmacokinetics and CNS drug delivery in an animal model. This information is used to determine ideal route of drug delivery (systemic, intrathecal, intranasal, convection-enhanced delivery) to achieve biologically effective dosing at the tumor site. Our animal models have chronically indwelling IV and CSF access, facilitating serial assessment of drug exposures in CSF fluid and the blood compartment simultaneously, allowing for multiple sample collection over time for PK studies. This model has been used to determine CSF and extracellular fluid penetration and toxicities of agents in development for patients with CNS tumors. Tumor type: all children's brain tumors; special focus on brainstem glioma. clinical trial design pharmacokinetics pharmacodynamics preclinical evaluation animal model glioma